"Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including in the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs."
Note: NASDAQ ADRs represent 10 Israeli shares.
BLRX - archive of related blog posts and articles
See below embedded slideshow for selected slides from the March 2012 investor conference presentation by BiolineRx management that summarizes key programs, catalysts, and financials.